PDS Biotechnology has called time on its phase 3 head and neck cancer therapy to channel resources to a drug in phase 2 development for metastatic colorectal cancer.
PDS Biotechnology has called time on its phase 3 head and neck cancer therapy to channel resources to a drug in phase 2 development for metastatic colorectal cancer.
